** Shares of drug developer Allakos ALLK.O rise 45.6% to 32 cents premarket
** Concentra Biosciences will buy Allakos for 33 cents per share in cash, a premium of 52% to ALLK's last close
** Allakos says a wholly owned subsidiary of Concentra will commence a tender offer by April 15 to acquire all outstanding shares of ALLK
** Co expects the deal to close in May 2025
** Says closing of the deal is subject to availability of at least $35.5 million of cash at closing, and other customary closing conditions
** Shares of the company have fallen 82.1% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.